NZ700760A - 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors - Google Patents
4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitorsInfo
- Publication number
- NZ700760A NZ700760A NZ700760A NZ70076013A NZ700760A NZ 700760 A NZ700760 A NZ 700760A NZ 700760 A NZ700760 A NZ 700760A NZ 70076013 A NZ70076013 A NZ 70076013A NZ 700760 A NZ700760 A NZ 700760A
- Authority
- NZ
- New Zealand
- Prior art keywords
- hydroxy
- hydroxylase inhibitors
- hif hydroxylase
- isoquinoline compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261609022P | 2012-03-09 | 2012-03-09 | |
| PCT/US2013/029912 WO2013134660A1 (en) | 2012-03-09 | 2013-03-08 | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ700760A true NZ700760A (en) | 2016-08-26 |
Family
ID=48014301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ700760A NZ700760A (en) | 2012-03-09 | 2013-03-08 | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9409892B2 (https=) |
| EP (1) | EP2834220B1 (https=) |
| JP (2) | JP6129217B2 (https=) |
| CN (1) | CN104470899B (https=) |
| AU (1) | AU2013229922B2 (https=) |
| CA (1) | CA2866556C (https=) |
| IL (1) | IL234544A (https=) |
| NZ (1) | NZ700760A (https=) |
| SG (1) | SG11201405574UA (https=) |
| WO (1) | WO2013134660A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2528232C (en) | 2003-06-06 | 2010-05-25 | Fibrogen, Inc. | Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| EP2872487B1 (en) | 2012-07-16 | 2017-04-26 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| KR20210130849A (ko) | 2012-07-16 | 2021-11-01 | 피브로겐, 인크. | 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형 |
| KR20210104173A (ko) | 2013-06-06 | 2021-08-24 | 피브로겐, 인크. | Hif 하이드록실라제 억제자의 약학적 제형 |
| WO2015054579A1 (en) * | 2013-10-11 | 2015-04-16 | Isis Pharmaceuticals, Inc. | Treatment of acute kidney injury with phd1 modulators |
| JP6506390B2 (ja) | 2014-09-02 | 2019-04-24 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | キノリノン系化合物及びその薬物への使用 |
| CN106146490B (zh) * | 2015-03-27 | 2018-10-23 | 沈阳三生制药有限责任公司 | 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途 |
| CN106146395B (zh) | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| CN105367435A (zh) * | 2015-12-03 | 2016-03-02 | 张伟 | 一种β-丙氨酸叔丁酯盐酸盐的制备方法 |
| CN107188875B (zh) * | 2016-03-15 | 2020-11-10 | 联化科技股份有限公司 | 一种取代苯酞类化合物的制备方法及其中间体 |
| CN106478503A (zh) * | 2016-09-29 | 2017-03-08 | 上海勋和医药科技有限公司 | Roxadustat中间体的制备方法 |
| EP3523279A1 (en) | 2016-10-10 | 2019-08-14 | Bristol-Myers Squibb Company | Tricyclic sulfones as ror gamma modulators |
| CN107954931B (zh) * | 2016-10-17 | 2021-06-22 | 上海医药集团青岛国风药业股份有限公司 | 一种诺得司他的制备方法 |
| CN110225753B (zh) | 2017-01-28 | 2022-12-09 | 金凯(辽宁)生命科技股份有限公司 | 用于制备5-苯氧基-1(3h)异苯并呋喃酮的方法 |
| TW201920108A (zh) * | 2017-09-25 | 2019-06-01 | 日商武田藥品工業有限公司 | N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物 |
| CN108084090B (zh) * | 2017-12-20 | 2020-03-17 | 北京六合宁远科技有限公司 | 一种药物中间体含氮杂环的溴代化合物的合成方法 |
| CN112679430B (zh) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| WO2021073623A1 (zh) * | 2019-10-18 | 2021-04-22 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| CN112679431B (zh) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| CN113754569B (zh) * | 2020-06-04 | 2024-07-02 | 四川国为制药有限公司 | 一种中间体化合物及其制备方法和用途 |
| WO2023072257A1 (en) | 2021-10-28 | 2023-05-04 | Insilico Medicine Ip Limited | Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof |
| CN118414327A (zh) * | 2021-12-17 | 2024-07-30 | 阿克比治疗有限公司 | 作为选择性phd1抑制剂的吡啶酰胺化合物、组合物和使用方法 |
| EP4447963A1 (en) * | 2021-12-17 | 2024-10-23 | Akebia Therapeutics Inc. | Selective phd1 inhibitor compounds, compositions, and methods of use |
| US20250099455A1 (en) * | 2022-01-13 | 2025-03-27 | Fibrogen, Inc. | Treatment for congestive heart failure |
| WO2024138317A1 (zh) * | 2022-12-26 | 2024-07-04 | 中国科学院广州生物医药与健康研究院 | 一种甲状腺激素受体β激动剂化合物及其制备方法和应用 |
| WO2024222890A1 (en) * | 2023-04-28 | 2024-10-31 | Insilico Medicine Ip Limited | Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof |
| KR20250174914A (ko) * | 2023-04-28 | 2025-12-15 | 인실리코 메디신 아이피 리미티드 | 결정질 프롤릴 하이드록실라제 도메인 포함 단백질(phd) 억제제 및 이의 용도 |
| EP4702028A1 (en) * | 2023-04-28 | 2026-03-04 | Insilico Medicine IP Limited | Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof |
| CN117486797A (zh) * | 2023-11-23 | 2024-02-02 | 传健生物医药(厦门)有限公司 | 一种罗沙司他关键中间体及罗沙司他的制备方法 |
| WO2025252553A1 (en) | 2024-06-04 | 2025-12-11 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036964A (en) | 1973-10-11 | 1977-07-19 | Beecham Group Limited | Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis |
| US3989704A (en) | 1973-10-30 | 1976-11-02 | Sandoz, Inc. | 3-Substituted-4-aryl isoquinolines |
| DE2818423A1 (de) | 1978-04-27 | 1979-11-08 | Hoechst Ag | Neue isochinolinderivate und verfahren zu ihrer herstellung |
| DE3233424A1 (de) | 1982-09-09 | 1984-03-15 | Hoechst Ag, 6230 Frankfurt | Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| US4559403A (en) | 1983-05-19 | 1985-12-17 | Hoffmann-La Roche Inc. | Substituted isoquinolines |
| US4584379A (en) | 1985-01-22 | 1986-04-22 | Merrell Dow Pharmaceuticals Inc. | Isoquinoline thromboxane synthetase inhibitors |
| US4822800A (en) | 1986-06-09 | 1989-04-18 | Ortho Pharmaceutical Corporation | Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties |
| US4952588A (en) | 1987-11-27 | 1990-08-28 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides |
| US4966906A (en) | 1987-11-27 | 1990-10-30 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-isoquinolinecarboxamides |
| ES2101420T3 (es) | 1993-11-02 | 1997-07-01 | Hoechst Ag | Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
| EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| AU4515696A (en) | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| WO1998023608A1 (en) | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| FR2779963A1 (fr) | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer |
| IT1302677B1 (it) | 1998-10-15 | 2000-09-29 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
| WO2000064877A1 (en) | 1999-04-26 | 2000-11-02 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
| IT1320162B1 (it) | 2000-02-09 | 2003-11-18 | Rotta Research Lab | Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico. |
| FI20002044A0 (fi) | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6716866B2 (en) | 2001-06-13 | 2004-04-06 | Genesoft Pharmaceuticals, Inc. | Aryl-benzimidazole compounds having antiinfective activity |
| US6777425B2 (en) | 2001-06-13 | 2004-08-17 | Genesoft Pharmaceuticals, Inc. | Isoquinoline compounds having antiinfective activity |
| US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| CN102552263A (zh) | 2001-12-06 | 2012-07-11 | 法布罗根股份有限公司 | 提高内源性红细胞生成素(epo)的方法 |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| CA2528232C (en) * | 2003-06-06 | 2010-05-25 | Fibrogen, Inc. | Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| CN100418948C (zh) | 2003-07-15 | 2008-09-17 | 麦克公司 | 羟基吡啶cgrp受体抗拮抗剂 |
| WO2005011696A1 (en) | 2003-08-01 | 2005-02-10 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005014533A2 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| DE602005016800D1 (de) | 2004-05-28 | 2009-11-05 | Fibrogen Inc | Hif-prolylhydroxylase-aktivitätstest |
| WO2006094292A2 (en) | 2005-03-02 | 2006-09-08 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| US20060276477A1 (en) | 2005-06-06 | 2006-12-07 | Fibrogen, Inc. | Treatment method for anemia |
| AU2006259352A1 (en) | 2005-06-15 | 2006-12-28 | Fibrogen, Inc. | Use of HIF 1alfa modulators for treatment of cancer |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| EP2476669A1 (en) * | 2006-01-27 | 2012-07-18 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
| CN103497184A (zh) | 2006-04-04 | 2014-01-08 | 菲布罗根有限公司 | 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物 |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| BRPI0713350B1 (pt) * | 2006-06-26 | 2022-04-12 | Akebia Therapeutics Inc | Composto, e, composição |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| EP2334682B1 (en) | 2008-08-20 | 2017-10-04 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| SI2373172T1 (sl) | 2008-12-03 | 2013-12-31 | Presidio Pharmaceuticals, Inc. | Inhibitorji HCV NS5A |
-
2013
- 2013-03-08 AU AU2013229922A patent/AU2013229922B2/en active Active
- 2013-03-08 WO PCT/US2013/029912 patent/WO2013134660A1/en not_active Ceased
- 2013-03-08 CN CN201380023358.XA patent/CN104470899B/zh active Active
- 2013-03-08 NZ NZ700760A patent/NZ700760A/en unknown
- 2013-03-08 JP JP2014561149A patent/JP6129217B2/ja not_active Expired - Fee Related
- 2013-03-08 US US14/383,874 patent/US9409892B2/en active Active
- 2013-03-08 SG SG11201405574UA patent/SG11201405574UA/en unknown
- 2013-03-08 CA CA2866556A patent/CA2866556C/en active Active
- 2013-03-08 EP EP13712970.6A patent/EP2834220B1/en active Active
-
2014
- 2014-09-09 IL IL234544A patent/IL234544A/en active IP Right Grant
-
2017
- 2017-03-13 JP JP2017047346A patent/JP2017101089A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1206743A1 (en) | 2016-01-15 |
| CN104470899B (zh) | 2017-12-26 |
| US20150038528A1 (en) | 2015-02-05 |
| JP2015509543A (ja) | 2015-03-30 |
| AU2013229922A1 (en) | 2014-10-23 |
| IL234544A (en) | 2017-03-30 |
| AU2013229922B2 (en) | 2017-09-28 |
| JP6129217B2 (ja) | 2017-05-17 |
| CA2866556C (en) | 2020-01-07 |
| CN104470899A (zh) | 2015-03-25 |
| EP2834220A1 (en) | 2015-02-11 |
| US9409892B2 (en) | 2016-08-09 |
| EP2834220B1 (en) | 2016-11-09 |
| WO2013134660A1 (en) | 2013-09-12 |
| SG11201405574UA (en) | 2014-10-30 |
| CA2866556A1 (en) | 2013-09-12 |
| JP2017101089A (ja) | 2017-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ700760A (en) | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors | |
| IN2015KN00265A (https=) | ||
| WO2012037155A3 (en) | Tyrosine kinase inhibitors | |
| JO2761B1 (en) | Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors | |
| WO2012129084A3 (en) | Glucosylceramide synthase inhibitors | |
| UA116092C2 (uk) | Спосіб та композиція для боротьби з бур'янами (варіанти) | |
| WO2010056767A8 (en) | Thiochromene derivatives as hif hydroxylase inhibitors | |
| PH12014500977A1 (en) | Compounds with nematicidal activity | |
| MY203474A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| TN2013000250A1 (en) | Prevention of adverse effects caused by cd3 specific binding domains | |
| MX350773B (es) | Métodos y composiciones para el control de malezas. | |
| UA116091C2 (uk) | Способи та композиції для боротьби з бур'янами | |
| MY167126A (en) | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
| SG195319A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| EA201590312A1 (ru) | Ферменты | |
| PH12015500515A1 (en) | Beta-glucosidase from magnaporthe grisea | |
| WO2013023084A3 (en) | Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells | |
| SG10201804952QA (en) | Glucosylceramide synthase inhibitors | |
| WO2009090394A3 (en) | Composition containing capsicum for treating a skin disorder | |
| WO2012099441A3 (ko) | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 | |
| WO2011127406A3 (en) | Acridines as inhibitors of haspin and dyrk kinases | |
| WO2014047519A3 (en) | Inhibitors of beta-hydrolase for treatment of cancer | |
| MX2017000184A (es) | Agentes de interaccion enzimatica. | |
| WO2011071541A3 (en) | Cadherin modulatory agents | |
| WO2012011741A3 (ko) | 신규한 푸사리세틴 화합물 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2018 BY CPA GLOBAL Effective date: 20170120 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2019 BY CPA GLOBAL Effective date: 20180125 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2020 BY CPA GLOBAL Effective date: 20190124 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2021 BY CPA GLOBAL Effective date: 20200213 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2022 BY CPA GLOBAL Effective date: 20210128 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2023 BY CPA GLOBAL Effective date: 20220121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2024 BY ANAQUA SERVICES Effective date: 20230221 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2025 BY ANAQUA SERVICES Effective date: 20240221 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2026 BY ANAQUA SERVICES Effective date: 20250219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2027 BY ANAQUA SERVICES Effective date: 20260219 |